Plus Therapeutics (PSTV) News Today → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free PSTV Stock Alerts $1.72 -0.01 (-0.58%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastasesfinance.yahoo.com - March 11 at 9:16 AMPlus Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 7 at 10:46 AMPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 7 at 10:46 AMQ4 2023 Plus Therapeutics Inc Earnings Callfinance.yahoo.com - March 6 at 6:24 PMPSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 5 at 10:33 PMPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlightsglobenewswire.com - March 5 at 4:05 PMIMUNON stock rallies 19% on early results for COVID-19 vaccinemsn.com - February 29 at 1:33 PMPlus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024finance.yahoo.com - February 27 at 8:49 AMPlus Therapeutics Inc PSTVmorningstar.com - February 21 at 6:55 PMPlus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024finanznachrichten.de - December 18 at 1:46 PMPlus Updates Financial and Cash Guidance for 2024finance.yahoo.com - December 18 at 8:46 AMPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analysesfinance.yahoo.com - December 12 at 10:20 AMAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)markets.businessinsider.com - November 29 at 8:56 AMFortress Biotech, Plus Therapeutics among healthcare moversmsn.com - November 20 at 2:51 PMPlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinarfinance.yahoo.com - November 20 at 9:51 AMPlus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023finance.yahoo.com - November 15 at 10:12 AMAnalysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)markets.businessinsider.com - November 3 at 7:54 AMPlus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastasesfinance.yahoo.com - November 3 at 7:54 AMWhy Plus Therapeutics Stock Popped Todaybenzinga.com - November 1 at 8:10 PMPlus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlightsfinanznachrichten.de - November 1 at 10:08 AMPlus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - October 31 at 5:46 PMPlus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinarfinance.yahoo.com - October 25 at 1:40 PMPlus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023finance.yahoo.com - October 23 at 6:40 PMPlus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in Octoberfinance.yahoo.com - October 9 at 7:59 AMTargeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSEfinance.yahoo.com - September 19 at 2:36 PMDirector Howard Clowes Buys 6,993 Shares of Plus Therapeutics Incfinance.yahoo.com - September 15 at 1:27 PMJonesTrading Sticks to Its Buy Rating for Plus Therapeutics (PSTV)markets.businessinsider.com - September 11 at 6:55 PMPlus Therapeutics gets $1.9M advance payment from CPRITmsn.com - September 11 at 6:55 PMPlus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conferencefinance.yahoo.com - September 11 at 7:17 AMBiocept gains on licensing pact with Plus Therapeutics for cancer testseekingalpha.com - September 9 at 5:12 PMPlus Fails to Find Traction on Licensing Agreementbaystreet.ca - September 8 at 5:43 PMBiocept (NASDAQ:BIOC) Skyrockets on Licensing Deal with Plus Therapeuticsmsn.com - September 8 at 5:43 PMWhy Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?finance.yahoo.com - September 8 at 5:43 PMPlus Therapeutics Expands Biocept Partnership with Diagnostic Platformfinance.yahoo.com - September 8 at 5:43 PMBiocept Signs CNSide™ Licensing Agreement with Plus Therapeuticsfinance.yahoo.com - September 8 at 8:55 AMPlus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastasefinance.yahoo.com - September 5 at 8:06 AMPlus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 30 at 9:23 AMPlus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - August 18 at 3:16 PMPlus Therapeutics Inc.: Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlightsfinanznachrichten.de - August 16 at 5:57 AMQ2 2023 Plus Therapeutics Inc Earnings Callfinance.yahoo.com - August 15 at 2:55 PMPlus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - August 14 at 8:24 PMH.C. Wainwright Keeps Their Buy Rating on Plus Therapeutics (PSTV)markets.businessinsider.com - August 14 at 10:02 AMPlus Therapeutics Earnings Previewbenzinga.com - August 11 at 7:26 PMPlus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conferencefinance.yahoo.com - August 11 at 7:26 PMEXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancerfinance.yahoo.com - August 11 at 7:26 PMPositive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeuticsfinance.yahoo.com - August 11 at 7:26 PMPlus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023finance.yahoo.com - August 8 at 5:35 PMPlus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conferencefinance.yahoo.com - August 8 at 12:34 PMPlus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conferencefinance.yahoo.com - August 3 at 7:41 AMPlus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operationsfinance.yahoo.com - July 28 at 9:40 AM Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Central Bank Gold Heist In Progress (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago. That's why we have released our Free Precious Metals Investment Guide. PSTV Media Mentions By Week PSTV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼1.370.63▲Average Medical News Sentiment PSTV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼01▲PSTV Articles Average Week Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NeuroMetrix News Today Titan Medical News Today Vapotherm News Today GlucoTrack News Today Vivos Therapeutics News Today PolyPid News Today Minerva Surgical News Today ProSomnus News Today Intelligent Bio Solutions News Today Acutus Medical News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.